Post-hoc analysis evaluates waist-to-height ratio improvements in adults treated with tirzepatide, suggesting lower cardiometabolic risks.
Key Points
This analysis aims to assess changes in waist-to-height ratio categories among adults treated with tirzepatide in the SURMOUNT-1 study. It explores the efficacy of tirzepatide in promoting better body composition outcomes.
Post hoc analysis of 2,538 participants from the SURMOUNT-1 Phase 3 trial.
Participants were randomized to receive tirzepatide (5, 10, or 15 mg) or placebo with a reduced-calorie diet and exercise.
Waist-to-height ratio categories were assessed using a mixed model for repeated measures. Shifts in categories were recorded from baseline to 72 and 176 weeks.
At baseline, 89.8% of participants had a WHtR > 0.59, and 0.1% had ≤ 0.49.
After 72 weeks, 16.7% of tirzepatide-treated participants achieved WHtR ≤ 0.49, compared to 9.6% with placebo.
At 176 weeks, among prediabetes participants, 12.2% achieved WHtR ≤ 0.49 with tirzepatide versus 9.3% with placebo.